Use of a Chinese medicine composition

Abstract

The present invention relates to the technical field of traditional Chinese medicine, and in particular to use of a traditional Chinese medicine composition in preparing a medicine having the function of preventing, treating, alleviating or improving depressive-like behavior, or in preparing a medicine having the function of reducing the level of inflammation in human or animal serum, or in preparing a medicine having the function of repairing the intestinal mucosal barrier of human or animal. The traditional Chinese medicine composition is prepared from the following medicinal raw materials: 6 to 12 parts of rose and 10 to 20 parts of schisandra chinensis. It has good safety and excellent effect. Animal experiments and clinical verification have shown that it has good effects for the above uses and is safer, and can be suitable for people of all ages to take.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to the use of a traditional Chinese medicine composition. Background Art

[0002] Depression is a common affective disorder characterized by low mood, insomnia, loss of interest in external things and activities, and other characteristics. Severe patients show slow thinking and weakened willpower, and may even have suicidal tendencies. Currently, clinical treatments are mainly serotonin reuptake inhibitors, tricyclic antidepressants, and tetracyclic antidepressants, but the above-mentioned therapeutic drugs have limitations such as long medication cycles, large side effects, high drug prices, and poor patient compliance. Based on this, it is imperative to seek more effective and safe treatment methods based on the characteristics of traditional Chinese medicine such as multiple targets and multiple pathways.

[0003] Traditional Chinese medicine believes that "depression" belongs to the category of "depression", "epilepsy" and "dryness". Rose is the dried bud of the rose of the Rosaceae family. It contains volatile oils, polyphenols, flavonoids and other chemical components, and has physiological activities such as anti-oxidation, anti-thrombosis, anti-cancer, antibacterial, immunomodulatory, hypolipidemic and heart disease prevention. At the same time, as the Chinese invention patent with document number CN109646526B discloses a Chinese medicine composition for treating depression and its preparation method. The Chinese medicine composition for treating depression, its active ingredients are made from the following raw materials: mint, wormwood, cassia seed, rose, kudzu root, angelica, albizzia, raw dragon bone, raw oyster, magnet, and nard. The Chinese medicine composition for treating depression uses aromatic Chinese medicine to make pills and fill them in the pillow to play the role of soothing the liver and relieving depression, calming the nerves and helping sleep, awakening the spleen and appetizing, and aromaticizing turbidity, thereby improving brain blood circulation. At the same time, the Chinese invention patent with document number CN113521185B also discloses a soothing Chinese medicine sachet, preparation method and use, which includes a variety of natural plant medicines including roses, which are made into sachets for wearing to effectively soothe and regulate people's tension, anxiety, and depression, and also provide an economical, simple and safe regulation method for the early stage of depression. However, as the technical solutions disclosed in the above patent documents are consistent, aromatherapy is often used in the prior art to improve depression, and its defects are slow onset, high cost, and long treatment cycle. Therefore, the prior art also needs a safe and more efficient oral Chinese medicine composition to improve and relieve depression.

[0004] Rose comes from "Food Materia Medica", its medicinal properties are slightly bitter, sweet, warm, return to the liver and spleen, widely used in beverages, food and other preparations, with high safety. At present, the medical use of rose has been extended to the anti-depression field, such as rose powder has anti-depressant effect, and the mice of forced swimming and tail suspension two behavioral despair depression models were gavaged with rose powder, which can significantly alleviate the depression symptoms of mice (Li Xiaoying, Qi Meifeng, Song Da, Shi Zhilong, Zhang Yi, Zhao Yunli, Yang Kunfen, Shang Jianhua. Anti-depressant activity and preliminary safety study of rose powder [J]. Yunnan Journal of Traditional Chinese Medicine, 2013, 34 (03): 46-48 + 89. DOI: 10.16254 / j.cnki.53-1120 / r.2013.03.036.). However, rose as a single active ingredient in clinical use, there is a slow onset and poor effect, and it also needs to be reasonably compatible to enhance its clinical effect. Summary of the invention

[0005] In order to solve the above technical problems, the purpose of the present invention is to provide a use of a Chinese medicine composition, which can be prepared into a medicine with significant antidepressant effect and good safety, and can be suitable for people of all ages to take.

[0006] In order to achieve the above technical effects, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a traditional Chinese medicine composition, which is prepared from the following medicinal raw materials: rose and Schisandra chinensis.

[0008] Preferably, in the above-mentioned traditional Chinese medicine composition, the mass proportions of rose and schisandra chinensis are: 6-12 parts of rose and 10-20 parts of schisandra chinensis, and more preferably 8 parts of rose and 10 parts of schisandra chinensis.

[0009] In a second aspect, the present invention also provides a use of a traditional Chinese medicine composition in preparing a medicine having the function of preventing, treating, alleviating or improving depressive-like behavior, or in preparing a medicine having the function of reducing the level of inflammation in human or animal serum, or in preparing a medicine having the function of repairing the intestinal mucosal barrier of humans or animals, wherein the traditional Chinese medicine composition is made of the following medicinal raw materials: rose and schisandra chinensis.

[0010] Preferably, the Chinese medicine composition is made of the following medicinal raw materials in parts by mass: 6 to 12 parts of rose and 10 to 20 parts of Schisandra chinensis.

[0011] Preferably, the Chinese medicine composition is made of the following medicinal raw materials in parts by mass: 7 to 9 parts of rose and 9 to 11 parts of Schisandra chinensis.

[0012] Further preferably, the above-mentioned traditional Chinese medicine composition is made of the following medicinal raw materials in the following parts by mass: 8 parts of rose and 10 parts of Schisandra chinensis.

[0013] Furthermore, the Chinese medicine composition is prepared together with pharmaceutically acceptable excipients as an oral medicine.

[0014] Preferably, the medicine is prepared as any one of pills, decoction pieces, tablets, pastes, powders, decoctions, granules, capsules, and pellets.

[0015] Furthermore, the drug having the function of preventing, treating, alleviating or improving depressive-like behavior exhibits at least any one of the functions of increasing the expression level of 5-HT in the hippocampus of humans or animals, increasing the expression level of BDNF in the hippocampus of humans or animals, increasing the expression level of NE in the hippocampus of humans or animals, and repairing neuronal damage in the brain of humans or animals.

[0016] Furthermore, the drug having the function of reducing the level of inflammation in human or animal serum is manifested as having at least any one of the functions of reducing the expression level of IL-6 in human or animal serum, reducing the expression level of interleukin-1β in human or animal serum, reducing the expression level of TNF-α in human or animal serum, and reducing the expression level of LPS in the serum of model group mice.

[0017] Furthermore, the drug having the function of repairing the intestinal mucosal barrier of humans or animals exhibits at least any one of the following functions: increasing the expression level of Occludin in the colon of humans or animals, increasing the expression level of Claudin-1 in the colon of humans or animals, increasing the expression level of ZO-1 in the colon of humans or animals, reducing the expression level of TNF-α in the colon tissue of humans or animals, reducing the expression level of IL-6 in the colon tissue of humans or animals, reducing the expression level of IL-1β mRNA in the colon tissue of humans or animals, and reducing the transcriptional expression level of LPS mRNA in the colon tissue of humans or animals.

[0018] In a third aspect, the present invention also provides a method for preparing the above-mentioned medicine, specifically:

[0019] S1: taking the drug raw materials according to the formula for extraction to obtain an extract;

[0020] S2: The extract obtained in S1 is concentrated until a viscous, nearly paste-like liquid is obtained, which is then prepared into a medicine.

[0021] Preferably, the extraction method in S1 is any one of decoction, immersion, percolation, reflux, solvent extraction, steam distillation, supercritical fluid extraction, ultrafine grinding technology, semi-bionic extraction, ultrasonic extraction, cyclone extraction or pressurized countercurrent extraction.

[0022] Preferably, S2 uses a reduced pressure concentration method to concentrate the drug solution, and the evaporation temperature is 40-42°C.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The invention provides a Chinese medicine composition, which is prepared by co-preparing rose and schisandra chinensis. The two drugs act synergistically and have the characteristics of high efficiency, good safety, mild and lasting effect. At the same time, based on the Chinese medicine composition, the invention further provides the use of the Chinese medicine composition, including the use in preparing a medicine with the function of preventing, treating, alleviating or improving depressive-like behavior, or the use in preparing a medicine with the function of reducing the level of inflammation in human or animal serum, or the use in preparing a medicine with the function of repairing the intestinal mucosal barrier of human or animal. At the same time, through animal experiments and clinical verification, the Chinese medicine composition has good effects in reducing the level of inflammation in human or animal serum, preventing, treating, alleviating or improving depressive-like behavior and repairing the intestinal mucosal barrier function of human or animal, etc., and can provide a Chinese medicine composition and medicine with good safety and good effect for clinical use, which can be suitable for people of all ages to take. The medicine prepared by the Chinese medicine composition can act on the human body through oral administration, has a faster onset speed, and has the characteristics of high efficiency, safety, and basically no side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The effect of the Chinese medicine composition of the present invention provided in Example 4 of the present invention on the damaged intestinal mucosal barrier of model mice;

[0026] Figure 2 The effect of the Chinese medicine composition of the present invention provided in Example 4 of the present invention on the expression levels of Occludin, Claudin-1 and ZO-1 in the colon of model mice. DETAILED DESCRIPTION

[0027] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0028] Unless otherwise specified, the test methods used in the following examples are all conventional methods; the materials, reagents or instruments used without indicating the manufacturer are all reagents and materials that can be obtained from commercial channels; if no specific conditions are specified in the examples, they are all carried out according to conventional conditions or conditions recommended by the manufacturer. At the same time, the present invention does not limit the sources of the raw materials used. Unless otherwise specified, the raw materials used in the present invention are all common commercial products in the technical field.

[0029] Example 1

[0030] This embodiment is the first preparation embodiment of the present invention. This embodiment provides a use of a Chinese medicine composition. The Chinese medicine composition specifically comprises the following medicinal raw materials by weight: 8 parts of rose flowers and 10 parts of Schisandra chinensis. The Chinese medicine composition is prepared as a decoction. The preparation method is as follows:

[0031] The drug raw materials are weighed according to the above mass fractions, and after being crushed, they are soaked in deionized water 10 to 15 times the volume of the drug raw materials for half an hour, boiled with high heat, then decocted with low heat for 30 minutes, filtered with gauze after decocting, and the drug residues are returned to the pot and decocted again for 2 times, and 10 times the volume of deionized water of the drug residues are added during the second decoction, and the drug residues are boiled with high heat, then decocted with low heat for 30 minutes, and the filtrate is taken; for the third decoction, 8 times the volume of deionized water of the drug residues are added, and the drug residues are boiled with high heat, then decocted with low heat for 30 minutes, and the filtrate is filtered, and the filtrates obtained after the three decoctions are combined to obtain a medicinal solution, which is cooled to obtain a decoction.

[0032] Example 2

[0033] This embodiment is the first preparation embodiment of the present invention. This embodiment provides a use of a Chinese medicine composition. The Chinese medicine composition specifically includes the following medicinal raw materials by weight: 8 parts of rose flowers and 10 parts of Schisandra chinensis. The Chinese medicine composition is prepared as an ointment. The preparation method is as follows:

[0034] S1: Weigh the drug raw materials according to the above mass fractions, and prepare them into a decoction according to the method of Example 1;

[0035] S2: The decoction obtained in S1 is further concentrated by a rotary evaporator. The specific operation is as follows: the cooled liquid is poured into a rotary evaporator in multiple times, and the liquid poured each time cannot exceed one third of the total volume of the rotary evaporator. The rotary evaporation temperature is controlled to 42°C, the rotation speed is adjusted to gear 4, the atmospheric pressure is first adjusted to 80 atmospheres, and after the rotary evaporation starts, the atmospheric pressure is reduced according to the situation until it is concentrated into a viscous, nearly paste-like liquid. The above-mentioned viscous, nearly paste-like liquid is poured into a glass container, and it is dried in a drying oven to a paste, thereby obtaining the ointment.

[0036] Example 3

[0037] This embodiment is the first preparation embodiment of the present invention. This embodiment provides a use of a Chinese medicine composition. The Chinese medicine composition specifically comprises the following medicinal raw materials by weight: 8 parts of rose and 10 parts of Schisandra chinensis. The Chinese medicine composition is prepared into tablets. The preparation method is as follows:

[0038] S1: Weigh the drug raw material according to the above mass fractions, use 50% ethanol as the extraction solvent for percolation extraction, soak the drug raw material with 1 to 3 times the volume of solvent before extraction, and then use 8 to 9 times the volume of solvent for extraction, the percolation extraction flow rate is controlled at 4 to 5 ml / min, and an extract is obtained after the extraction is completed;

[0039] S2: The extract obtained in S1 is further subjected to reduced-pressure rotary evaporation by a rotary evaporator to obtain a viscous, nearly paste-like liquid, and auxiliary materials including fillers and lubricants are added to the above-mentioned viscous, nearly paste-like liquid, and then prepared into tablets by wet granulation, wherein the above-mentioned fillers and lubricants can be selected from the existing technology.

[0040] Example 4

[0041] This example verifies the efficacy and studies the mechanism of the Chinese medicine composition provided by the present invention. The experimental methods and materials are as follows:

[0042] SPF grade C57BL / 6J male mice weighing 20±2 g were used as experimental materials and randomly divided into a blank group, a model group, a control group 1 (rose group), a control group 2 (Schisandra chinensis group) and Example 4 group according to experimental needs.

[0043] During the experiment, each group of mice was first adaptively raised for one week, and then the CUMS combined solitary mouse model was replicated. The stressors of the CUMS combined solitary mouse model included fasting (12h), water deprivation (12h), wet cage (12h), cage tilting (12h), tail clamping (1min), restraint (1h), night lighting (12h), and pair living (12h). Two stressors were randomly used every day, and the same stressor should not appear continuously. Each stressor should not appear more than twice a week, and the modeling period was 5 weeks.

[0044] After successful modeling, drug intervention was performed. Control group 1 used rose as the drug at a dosage of 2.08 g / kg; control group 2 used Schisandra chinensis as the drug at a dosage of 2.6 g / kg; Example 4 group used rose and Schisandra chinensis prepared as a decoction in a mass ratio of 4:5 as the drug (prepared with reference to Example 1), with a dosage of 2.34 g / kg. The drugs for control group 1, control group 2 and Example 4 were prepared by referring to the decoction preparation method in Example 1.

[0045] 4.1 Effect of the Chinese medicine composition of the present invention on the behavior of model mice

[0046] The sucrose preference test (SPT) is one of the most important macro-indicators for determining depression. It can intuitively express the degree of anhedonia in mice, and quickly and intuitively reflect whether the mice have established a model and the therapeutic effect of the drug. The open field test (OFT) can detect the spontaneous movement ability and exploratory behavior of mice. The forced swimming test (FST) generally uses the immobility time to evaluate the despair state of mice.

[0047] Therefore, the present invention conducts a sugar water preference test, an open field test, and a forced swimming test to observe the effect of the Chinese medicine composition provided by the present invention on the behavior of each group of mice. The experimental method is:

[0048] Sugar water preference test (SPT): During the adaptation phase, weigh 2 bottles of 50 ml of 1% sugar water and place them on the mouse cage, and let the mice drink water freely for 24 hours. Weigh 1 bottle of 50 ml of 1% sugar water and 50 ml of drinking water and place them on the mouse cage, and let the mice drink water freely for 24 hours. At the beginning of the formal experiment, the mice were fasted from food and water for 24 hours, and 1 bottle of 50 ml drinking water and 1 bottle of 50 ml 1% sugar water were placed in the mouse cage respectively, and let the mice drink water freely for 3 hours. After 3 hours, the positions of the drinking water bottle and the sugar water bottle were exchanged, and the mice were allowed to drink water freely for 3 hours. Finally, the water bottles were removed to weigh the remaining amount (%) inside.

[0049] Open field test (OFT): The mice were placed in an open field box, which was divided into a 3×3 grid in the VisuTrack high-end animal behavior analysis system, and the total distance (mm) of the mice in the open field box was recorded.

[0050] Forced swimming test (FST): The mice were placed in a swimming bucket and forced to swim for 6 minutes. The time (s) that the mice remained immobile for the next 4 minutes was recorded using an analysis system.

[0051] The experimental results of the sucrose preference test (SPT), open field test (OFT) and forced swimming test (FST) are shown in Table 1:

[0052] Table 1 Effects of the composition of the present invention on the behavior of model mice

[0053]

[0054] Note: Compared with the control group, * p<0.05, ** p<0.01; compared with the model group, # p<0.05, ## p<0.01.

[0055] The above experimental results show that compared with the blank group, the sugar water preference percentage of mice in the model group was significantly decreased (p < 0.01), and the sugar water preference percentage of mice in control group 1 and control group 2 was significantly increased relative to that of the model group (p < 0.01), but the effects were inferior to those of Example 4 group.

[0056] Compared with the blank group, the total path of the open field test in the model group mice was significantly downregulated (p < 0.05); the Example 4 group showed an upregulation trend (p > 0.05), and the effect was significantly better than that of the control group 1 and the control group 2.

[0057] Compared with the blank group, the forced swimming floating time of the model group was significantly increased (p < 0.01); the expression of Example 4 group was significantly downregulated (p < 0.01), and the effect was better than that of control group 1 and control group 2.

[0058] 4.2 Effect of the Chinese medicine composition of the present invention on the expression of 5-HT and BDNF in the hippocampus of model mice

[0059] The concentration of 5-HT in brain tissue is high. It is an important substance that regulates neural activity. In the process of mood disorders, 5-HT can regulate the nervous system and is considered to be the main biological matrix. BDNF is a growth factor for 5-HT amine neurons. It is expressed in large quantities in the hippocampus and can bind to its specific receptor tyrosine kinase B (TrkB) through a variety of secretion methods, promoting the phosphorylation of intracellular cyclic adenosine monophosphate response element binding protein (CREB) to improve depressive symptoms.

[0060] In this example, after the administration, the 5-HT and BDNF contents in the mouse hippocampus were detected and compared by ELISA method to reflect the effect of the Chinese medicine composition provided by the present invention on the mouse brain tissue. The detection results are shown in Table 2.

[0061] Table 2 Effects of the composition of the present invention on the expression of 5-HT and BDNF in the hippocampus of model mice

[0062]

[0063] Note: Compared with the control group, * p<0.05, ** p<0.01: comparison between treatment group and model group, # p<0.05, ## p<0.01.

[0064] The experimental results showed that compared with the blank group, the levels of 5-HT and BDNF in the hippocampus of mice in the model group were significantly decreased (p < 0.01), while the expressions of 5-HT and BDNF in the Example 4 group were significantly upregulated (p < 0.01).

[0065] 4.3 Effects of the Chinese medicine composition of the present invention on intestinal mucosal barrier and colon inflammation in model mice

[0066] 4.3.1 Effect of the Chinese medicine composition of the present invention on the damaged intestinal mucosal barrier of model mice

[0067] The intestinal mucosal barrier is damaged, its integrity is destroyed, harmful bacteria and their metabolites in the intestine increase, and intestinal LPS can enter the blood through the damaged intestinal mucosal barrier, causing the body to be in long-term chronic inflammation. Therefore, after the administration, the colon tissues of mice in each group were taken for HE staining to observe the degree of inflammatory infiltration of colon tissue and the degree of mucosal damage.

[0068] The experimental results are as attached Figure 1 As shown, the experimental results show that: compared with the blank group, the intestinal mucosal villi of the mice in the model group were defective with inflammatory cell infiltration, and the mucosal muscular layer was thinned, while the intestinal mucosal glands of the Example 4 group were relatively complete, the mucosal epithelial cell structure was relatively complete, and the inflammatory cell infiltration was reduced.

[0069] In addition, tight junction proteins Occludin, claudin-1, and ZO-1 are the basic structures of the intestinal mucosal mechanical barrier and can maintain its permeability. Therefore, this example further uses Western blot to detect the relative expression levels of tight junction proteins Occludin, Claudin-1, and ZO-1 in the colon of each group of mice. The experimental results are shown in Table 3 and Appendix. Figure 2 As shown:

[0070] Table 3 Effects of the composition of the present invention on the relative expression levels of Occludin, Claudin-1 and ZO-1 in model mice

[0071]

[0072] Note: Compared with the control group, * p<0.05, ** p<0.01; compared with the model group, # p<0.05, ## p<0.01.

[0073] The experimental results showed that compared with the blank group, the relative expression levels of colon tight junction proteins Occludin, Claudin-1, and ZO-1 in the model group were significantly downregulated (p < 0.01), and the relative expression levels of colon tight junction proteins Occludin, Claudin-1, and ZO-1 in the Example 4 group were significantly upregulated (p < 0.05).

[0074] 4.3.2 Effect of the Chinese medicine composition of the present invention on the transcriptional expression levels of TNF-α, IL-6 and IL-1β mRNA in colon tissue of model mice

[0075] Long-term chronic stress can cause persistent damage to the intestinal mucosa, destroy the integrity of the intestinal mucosa, and cause enteric endotoxins to enter the blood, causing the body's inflammation level to increase, and even causing changes in the permeability of the blood-brain barrier, thereby affecting the content of neurotransmitters in the hippocampus. Therefore, this example further detected the transcriptional expression levels of TNF-α, IL-6, and IL-1β mRNA in the colon tissues of each group of mice, and the test results are shown in Table 4:

[0076] Table 4 Effects of the composition of the present invention on the transcriptional expression levels of TNF-α, IL-6 and L-1β mRNA in model mice

[0077]

[0078] Note: Compared with the control group, * p<0.05, ** p<0.01; compared with the model group, # p<0.05, ## p<0.01.

[0079] The experimental results show that: compared with the blank group, the transcriptional expression levels of TNF-α, IL-6, and IL-1β mRNA in the colon tissue of the model group were significantly upregulated (p < 0.05); the transcriptional expression levels of TNF-α, IL-6, and IL-1β mRNA in the colon tissue of the Example 4 group were significantly downregulated (p < 0.05).

[0080] 4.3.3 Effect of the Chinese medicine composition of the present invention on the transcriptional expression level of LPS mRNA in colon tissue of model mice

[0081] After the administration, RT-PCR was used to detect the transcription level of LPS mRNA in colon tissue. The experimental results are shown in Table 5:

[0082] Table 5 Effect of the composition of the present invention on the transcriptional expression level of LPS mRNA in colon tissue of model mice

[0083]

[0084] Wa: Comparison between the model group and the control group, * p<0.05, ** p<0.01: comparison between treatment group and model group, # p<0.05, ## p<0.01.

[0085] The experimental results showed that: compared with the blank group, the transcriptional expression level of LPS mRNA in the colon tissue of the model group mice was significantly upregulated (p < 0.01); compared with the model group, the transcriptional expression level of LPS mRNA in the colon tissue of the Example 4 group was significantly downregulated (p < 0.05).

[0086] 4.4 Effect of the Chinese medicine composition of the present invention on changes related to serum inflammation levels in mice

[0087] 4.4.1 Effect of the Chinese medicine composition of the present invention on the level of LPS in the serum of model mice

[0088] LPS is more easily absorbed into the blood after the intestinal barrier function is damaged, thereby inducing the release of peripheral and central pro-inflammatory cytokines, further aggravating the inflammatory response. Therefore, the present invention detects the expression level of lipopolysaccharide in the serum of each group of mice, and the experimental results are shown in Table 6:

[0089] Table 6 Effect of the composition of the present invention on the level of LPS in the serum of model mice

[0090]

[0091] Note: Compared with the control group, * p<0.05, ** p<0.01; compared with the model group, # p<0.05, ## p<0.01.

[0092] The experimental results showed that compared with the blank group, the serum LPS content of the model group mice increased significantly (p < 0.01). The LPS expression of Example 4 group was significantly downregulated (p < 0.05).

[0093] 4.4.2 Effect of the Chinese medicine composition of the present invention on the levels of IL-6, IL-1β and TNF-α in the serum of model mice

[0094] The present invention detects the expression levels of IL-6, IL-1β, and TNF-α in the serum of each group of mice. The experimental results are shown in Table 7:

[0095] Table 7 Effect of the composition of the present invention on the levels of IL-6, IL-1β and TNF-α in the serum of model mice

[0096]

[0097] Note: Compared with the control group, * p<0.05, ** p<0.01; compared with the model group, # p<0.05, ## p<0.01.

[0098] The above experimental results show that the Chinese medicine composition for repairing the intestinal mucosal barrier and alleviating depressive-like behavior provided in this embodiment can achieve the anti-depressant effect by repairing the intestinal mucosal barrier, reducing the entry of endotoxin into the blood, and regulating the expression of neurotransmitters, and its effect is significant.

[0099] Based on the above studies, it is proved that the Chinese medicine composition for repairing the intestinal mucosal barrier and relieving depressive-like behavior provided by the present invention can effectively relieve depressive-like behavior, and can provide a Chinese medicine composition with good safety and good effect for clinical practice.

[0100] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the purpose and scope of the technical solutions of the present invention, which should be included in the scope of the claims of the present invention. The techniques, shapes, and structural parts not described in detail in the present invention are all known technologies.

Claims

1. A Chinese medicine composition for improving depressive-like behavior, characterized in that: The method is prepared from the following medicinal raw materials in parts by weight: 8 parts of rose flowers and 10 parts of schisandra chinensis.

2. Use of a Chinese medicine composition in the preparation of a medicine having the function of improving depressive-like behavior, wherein the Chinese medicine composition is made of the following medicinal raw materials in parts by mass: 8 parts of rose and 10 parts of Schisandra chinensis.

3. The use according to claim 2, characterized in that: The Chinese medicine composition is prepared together with pharmaceutically acceptable excipients as an oral medicine.

4. The use according to claim 2, characterized in that: The drug having the function of improving depressive-like behavior exhibits at least one of the functions of increasing the expression level of 5-HT in the hippocampus of humans or animals and increasing the expression level of BDNF in the hippocampus of humans or animals.

5. The use according to claim 2, characterized in that The Chinese medicine composition is prepared according to the following method: S1: taking the drug raw materials according to the formula for extraction to obtain an extract; S2: The extract obtained in S1 is concentrated until a viscous, nearly paste-like liquid is obtained, and then the liquid is prepared into an oral preparation.

6. The use according to claim 5, characterized in that The S2 uses a reduced pressure concentration method to concentrate the liquid medicine, and the evaporation temperature is 40-42°C.

Images